News
Public · Published
Scotiabank maintains Pfizer at Sector Outperform, raises price target to $35 from $33
Scotiabank kept its Sector Outperform rating on Pfizer and raised its price target to $35 from $33, an increase of 6.1%. The new target implies 13.7% upside from Pfizer's November 4 closing price of $30.79.
Published:
Updated:
What happened
Scotiabank kept its Sector Outperform rating on Pfizer and raised its price target to $35 from $33, an increase of 6.1%. The new target implies 13.7% upside from Pfizer’s November 4 closing price of $30.79.
Confirmed
Global impact / market context
The higher target signals that Scotiabank sees more potential value in Pfizer shares, but it is an analyst estimate rather than a company result or guarantee. If investors act on that view, buying could support the share price; the article reports no market reaction.
Analyst inference
The article lists other analyst views as Neutral or Sector Perform, with targets from $28 to $33. Scotiabank’s raised target is higher than those listed targets and its previous target, but these are analyst opinions, not company results or guaranteed share prices.
Analyst inference
What to watch
- Compare future analyst ratings and targets with Scotiabank’s $35 estimate; changes in those views could influence investor expectations for Pfizer shares. Analyst inference
- Check whether Pfizer’s later company results support the optimism behind Scotiabank’s higher target; this article provides no operating results or explanation for the increase. Analyst inference
- The article says $35 implies 13.7% upside from the November 4 close of $30.79; that comparison is an estimate, not a promised return. Confirmed
Evidence
- Original source link unavailable